Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

DRUG SAMPLES SHOULD BE DISCONTINUED, NABP DECLARES IN RESOLUTION forwarded to the pharmaceutical industry. The resolution resulted from discussion of diversion-related issues by the Georgia Drugs & Narcotics Agency at the recent annual meeting of the Natl. Assn. of Boards of Pharmacy (NABP). NABP "has been aware of the growing trend in which many drug whslrs. deal in diverted drugs, as well as the number of new drug whslrs. springingup strictly for the purpose of brokering samples and diverted drugs," NABP President-Elect Eugene Argo said in a statement. Argo is a member of the Georgia Pharmacy Board. NABP-urges its member boards "to look closely" at the FBI's Georgia-based investigation of drug diversion, "When a licentiate in their state is convicted of such crimes or otherwise proven to have committed such violations, we urge that state board of pharmacy to take strong, swift and just action," Argo said. The Georgia Pharmacy Board said it plans to introduce legislation in the General Assembly in 1986 banning the sampling of all Rx drugs in Georgia. One of the Georgia board's members is Neil Pruitt, past-president of the Natl. Assn. of Retail Druggists, which has proposed for some time the ban of Rx drug samples. "As a result of this [FBI] investigation and the findings regarding the methods by which drug samples are being misused, it is obvious that it is impossible to insure that the integrity of drug samples have been maintained and have not become adulterated," the Georgia board said.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts